Generics giant Teva turns to branded drugs R&D for its futurenews2025-06-05T17:47:42+00:00June 5th, 2025|Endpoints News|
Restarted auction for 23andMe comes with $305M offer from former CEO Anne Wojcickinews2025-06-05T11:15:55+00:00June 5th, 2025|Endpoints News|
After layoffs, Casma eyes path to clinic with autophagy-boosting drugnews2025-06-04T19:24:35+00:00June 4th, 2025|Endpoints News|
Ex-HHS workers accuse Kennedy of relying on flawed data to issue firingsnews2025-06-04T17:11:37+00:00June 4th, 2025|Endpoints News|
Struggling biotechs succumb to icy market, as money dries up and clinical bets don’t pay offnews2025-06-04T14:00:32+00:00June 4th, 2025|Endpoints News|
Pharma companies rush in to buy what they hope will rival Keytrudanews2025-06-03T20:12:08+00:00June 3rd, 2025|Endpoints News|
Makary tells Hawley he will review the abortion pill mifepristonenews2025-06-03T17:35:00+00:00June 3rd, 2025|Endpoints News|
Q&A: Sandoz CEO talks generic GLP-1s, Trump’s tariffs, Mark Cuban’s companynews2025-06-03T11:00:52+00:00June 3rd, 2025|Endpoints News|
#ASCO25: Enhertu combo has the makings of a new standard in HER2-positive breast cancernews2025-06-02T12:00:10+00:00June 2nd, 2025|Endpoints News|
Bristol Myers and BioNTech make $1.5B upfront deal for PD-L1xVEGF cancer drugnews2025-06-02T10:45:32+00:00June 2nd, 2025|Endpoints News|
